FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Discovery · preclinical Keeps selling its lead antiplatelet while widening new-drug development under a government support programme. Also seen: Commercial · sales

  • Selected for the government World Class Plus project with candidates including an immune and inflammation drug. Source

Roles often seen at this stageResearch & development · Sales & marketing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

Samjin Pharmaceutical

A pharmaceutical company selling prescription drugs such as the antiplatelet Plaless, while developing new-drug candidates including an immune and inflammation programme.

Plaless

Marketed

Clopidogrel antiplatelet launched in 2007 that leads the company's sales growth.

SJN314

Stage unconfirmed

Immune and inflammation drug candidate selected for a government R&D support programme.

Announced

Selected for the government's World Class Plus project support.

Official role guide

Samjin Pharmaceutical careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 삼진제약, '2026 월드클래스 플러스 프로젝트' 선정 ↗이투데이 · Published 2026-10-06 · Sources checked 2026-11-15 · Original unavailable
  2. 삼진제약, 상반기 매출 선방…항혈전제 '플래리스' 견인 ↗딜사이트 · Published Date unconfirmed · Sources checked 2026-11-15 · Original unavailable